Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207037 | 0.98 | AKR1B1 (0.52) | AKR1B1PAOXGPR84PPARGPPARD | |
| SCHEMBL30438247 | 0.98 | AKR1B1 (0.52) | AKR1B1PAOXGPR84PPARGPPARD | |
| SCHEMBL18937729 | 0.93 | AKR1B1 (0.58) | AKR1B1PAOXGPR84PPARGPPARD | |
| Adipic Acid SCHEMBL10889377 | 0.93 | AKR1B1 (0.64) | AKR1B1PAOXGPR84PPARGPPARD | |
| Adipic Acid SCHEMBL10889382 | 0.93 | AKR1B1 (0.64) | AKR1B1PAOXGPR84PPARGPPARD | |
| SCHEMBL30305275 | 0.91 | GPR84 (0.60) | AKR1B1PAOXGPR84PPARGPPARD | |
| SCHEMBL7422875 | 0.91 | GPR84 (0.60) | AKR1B1PAOXGPR84PPARGPPARD | |
| SCHEMBL30678648 | 0.91 | GPR84 (0.60) | AKR1B1PAOXGPR84PPARGPPARD | |
| SCHEMBL27240998 | 0.91 | GPR84 (0.60) | AKR1B1PAOXGPR84PPARGPPARD | |
| SCHEMBL18797893 | 0.91 | GPR84 (0.60) | AKR1B1PAOXGPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372542-A1 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | UNIV CALIFORNIA (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116670769-A | Compositions and methods for modulating TCF4 gene expression and treating petehypgold syndrome | 加利福尼亚大学董事会 | 2023-08-29 | — | — | CN | disclosed |
| EP-4222268-A1 | COMPOSITIONS AND METHODS FOR MODULATING TCF4 GENE EXPRESSION AND TREATING PITT HOPKINS SYNDROME | The Regents of The University of California (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-110099682-B | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022072709-A1 | COMPOSITIONS AND METHODS FOR MODULATING TCF4 GENE EXPRESSION AND TREATING PITT HOPKINS SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3736306-A1 | RECOVERY OF FIBERS FROM FIBER REINFORCED POLYMERS WITH LEWIS BASES | The Boeing Company (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2020193431-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-10-01 | — | — | WO | disclosed |
| US-20170275305-A1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | SHINETSU CHEMICAL CO (JP) | 2017-09-28 | — | — | US | disclosed |
| EP-2925721-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-1211239-A1 | PROCESS FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| CN-1053472-C | Oligonucleotides derived from the SOD family | HOFFMANN LA ROCHE (CH) | 2000-06-14 | — | — | CN | disclosed |
| CN-1106405-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | CN | disclosed |
| US-4734424-A | ANTICOAGULANTS | E. R. SQUIBB & SONS, INC. (US) | 1988-03-29 | — | — | US | disclosed |
| US-4663336-A | ANTICOAGULANTS | E. R. SQUIBB & SONS, INC. (US) | 1987-05-05 | — | — | US | disclosed |
| US-4638012-A | 7-oxabicycloheptane α-substituted ketone prostaglandin analogs useful in the treatment of thrombotic disease | E. R. SQUIBB & SONS, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0207684-A2 | 7-Oxabicycloheptane substituted diamide and its congener prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4632931-A | ANTICOAGULANTS, BRONCHODILATOR AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275305-A1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | ADH1A, ADH1C, AP3M1 | AKR1B1 199/4885PAOX 1521/4885GPR84 2961/4885 |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | AKR1B1 62/4885PAOX 2160/4885GPR84 983/4885 |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | AKR1B1 62/4885PAOX 2160/4885GPR84 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.